PT1860101E - Sal de tartrato da isofagomina e métodos de uso - Google Patents
Sal de tartrato da isofagomina e métodos de uso Download PDFInfo
- Publication number
- PT1860101E PT1860101E PT07252109T PT07252109T PT1860101E PT 1860101 E PT1860101 E PT 1860101E PT 07252109 T PT07252109 T PT 07252109T PT 07252109 T PT07252109 T PT 07252109T PT 1860101 E PT1860101 E PT 1860101E
- Authority
- PT
- Portugal
- Prior art keywords
- isofagomine
- tartrate
- sale
- methods
- salt
- Prior art date
Links
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 title 1
- QPYJXFZUIJOGNX-HSUXUTPPSA-N afegostat Chemical compound OC[C@H]1CNC[C@@H](O)[C@@H]1O QPYJXFZUIJOGNX-HSUXUTPPSA-N 0.000 title 1
- 229940095064 tartrate Drugs 0.000 title 1
- ULBPPCHRAVUQMC-MUMXBIPUSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;(3r,4r,5r)-5-(hydroxymethyl)piperidine-3,4-diol Chemical compound OC[C@H]1CNC[C@@H](O)[C@@H]1O.OC(=O)[C@H](O)[C@@H](O)C(O)=O ULBPPCHRAVUQMC-MUMXBIPUSA-N 0.000 abstract 2
- 208000015872 Gaucher disease Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003892 tartrate salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80802006P | 2006-05-24 | 2006-05-24 | |
| US89071907P | 2007-02-20 | 2007-02-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1860101E true PT1860101E (pt) | 2011-07-12 |
Family
ID=38462442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT07252109T PT1860101E (pt) | 2006-05-24 | 2007-05-23 | Sal de tartrato da isofagomina e métodos de uso |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7501439B2 (enExample) |
| EP (1) | EP1860101B1 (enExample) |
| JP (1) | JP5292605B2 (enExample) |
| AT (1) | ATE504570T1 (enExample) |
| AU (1) | AU2007202359B2 (enExample) |
| BR (1) | BRPI0706114A2 (enExample) |
| CA (1) | CA2590122C (enExample) |
| DE (1) | DE602007013648D1 (enExample) |
| DK (1) | DK1860101T3 (enExample) |
| IL (1) | IL183415A (enExample) |
| MX (1) | MX2007006175A (enExample) |
| PL (1) | PL1860101T3 (enExample) |
| PT (1) | PT1860101E (enExample) |
| WO (1) | WO2007140212A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006254796B2 (en) * | 2005-06-08 | 2012-08-16 | Amicus Therapeutics, Inc. | Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes |
| BRPI0713442A2 (pt) | 2006-06-23 | 2012-03-06 | Amicus Therapeutics, Inc. | Método para o tratamento de desrodens neurológicas, pelo aumento da atividade de b-glicocerebrosidase |
| WO2008144773A1 (en) | 2007-05-22 | 2008-11-27 | Amicus Therapeutics, Inc. | New method for preparing isofagomine and its derivatives |
| WO2009102895A2 (en) | 2008-02-12 | 2009-08-20 | Amicus Therapeutics, Inc. | Method to predict response to pharmacological chaperone treatment of diseases |
| AU2009314447A1 (en) * | 2008-11-14 | 2010-05-20 | Neuraltus Pharmaceuticals, Inc. | Compositions and methods for the treatment of altered alpha-synuclein function |
| CN109172813B (zh) | 2009-07-28 | 2022-09-02 | 武田药品工业株式会社 | 用于治疗戈谢病的组合物和方法 |
| RU2608520C2 (ru) * | 2009-10-19 | 2017-01-19 | Амикус Терапьютикс, Инк. | Новые композиции для предупреждения и/или лечения лизосомных болезней накопления |
| LT2490532T (lt) | 2009-10-19 | 2017-03-27 | Amicus Therapeutics, Inc. | Naujos kompozicijos centrinės nervų sistemos degeneratyvinių sutrikimų profilaktikai ir (arba) gydymui |
| DK2707101T3 (da) | 2011-05-12 | 2019-05-13 | Proteostasis Therapeutics Inc | Proteostaseregulatorer |
| WO2012177997A1 (en) | 2011-06-22 | 2012-12-27 | The General Hospital Corporation | Treatment of proteinopathies |
| AU2013202368B2 (en) | 2012-01-25 | 2016-06-16 | Proteostasis Therapeutics, Inc. | Proteasome activity modulating compounds |
| AU2013225816B2 (en) | 2012-03-02 | 2017-10-26 | Takeda Pharmaceutical Company Limited | Compositions and methods for treating Type III Gaucher Disease |
| ES2924829T3 (es) | 2012-03-27 | 2022-10-11 | Amicus Therapeutics Inc | Compuestos novedosos para prevenir y/o tratar tesaurismosis lisosómicas y/o trastornos degenerativos del sistema nervioso central |
| JP2015512913A (ja) | 2012-03-28 | 2015-04-30 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | グルコセレブロシダーゼ活性剤として有用なサリチル酸誘導体 |
| EP3318277A1 (en) | 2016-11-04 | 2018-05-09 | Institut du Cerveau et de la Moelle Epiniere-ICM | Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases |
| DE102017103346A1 (de) * | 2017-02-17 | 2018-08-23 | Lts Lohmann Therapie-Systeme Ag | Strukturierte orodispergierbare Filme |
| CN111278439A (zh) * | 2017-10-26 | 2020-06-12 | 夏尔人类遗传性治疗公司 | 包含葡萄糖脑苷脂酶和异烟肼的调配物 |
| MX2020014082A (es) | 2018-06-27 | 2021-04-13 | Proteostasis Therapeutics Inc | Compuestos que mejoran la actividad del proteasoma. |
| JP7551087B2 (ja) | 2018-06-27 | 2024-09-17 | キネタ， インコーポレイテッド | プロテアソーム活性増強化合物 |
| WO2020023390A1 (en) | 2018-07-25 | 2020-01-30 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
| JP7642561B2 (ja) * | 2019-04-25 | 2025-03-10 | 武田薬品工業株式会社 | イソファゴミン塩、その使用方法および製剤 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5844102A (en) * | 1994-07-07 | 1998-12-01 | University Of Maryland Baltimore County | Glycohydrolase inhibitors, their preparation and use thereof |
| US6274597B1 (en) * | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
-
2007
- 2007-05-23 PL PL07252109T patent/PL1860101T3/pl unknown
- 2007-05-23 DE DE602007013648T patent/DE602007013648D1/de active Active
- 2007-05-23 US US11/752,658 patent/US7501439B2/en active Active
- 2007-05-23 EP EP07252109A patent/EP1860101B1/en not_active Not-in-force
- 2007-05-23 AT AT07252109T patent/ATE504570T1/de active
- 2007-05-23 PT PT07252109T patent/PT1860101E/pt unknown
- 2007-05-23 DK DK07252109.9T patent/DK1860101T3/da active
- 2007-05-23 WO PCT/US2007/069550 patent/WO2007140212A2/en not_active Ceased
- 2007-05-23 MX MX2007006175A patent/MX2007006175A/es active IP Right Grant
- 2007-05-24 CA CA 2590122 patent/CA2590122C/en not_active Expired - Fee Related
- 2007-05-24 AU AU2007202359A patent/AU2007202359B2/en not_active Ceased
- 2007-05-24 IL IL183415A patent/IL183415A/en active IP Right Grant
- 2007-05-24 JP JP2007138358A patent/JP5292605B2/ja not_active Expired - Fee Related
- 2007-05-24 BR BRPI0706114-5A patent/BRPI0706114A2/pt not_active Application Discontinuation
-
2009
- 2009-02-23 US US12/391,049 patent/US7863453B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20070281975A1 (en) | 2007-12-06 |
| EP1860101B1 (en) | 2011-04-06 |
| WO2007140212A2 (en) | 2007-12-06 |
| JP5292605B2 (ja) | 2013-09-18 |
| AU2007202359B2 (en) | 2012-02-16 |
| IL183415A0 (en) | 2007-09-20 |
| US7863453B2 (en) | 2011-01-04 |
| CA2590122A1 (en) | 2007-11-24 |
| BRPI0706114A2 (pt) | 2008-11-18 |
| US20090176830A1 (en) | 2009-07-09 |
| DE602007013648D1 (de) | 2011-05-19 |
| CA2590122C (en) | 2015-03-31 |
| MX2007006175A (es) | 2009-02-16 |
| US7501439B2 (en) | 2009-03-10 |
| ATE504570T1 (de) | 2011-04-15 |
| EP1860101A1 (en) | 2007-11-28 |
| JP2007314540A (ja) | 2007-12-06 |
| IL183415A (en) | 2012-03-29 |
| DK1860101T3 (da) | 2011-07-25 |
| PL1860101T3 (pl) | 2011-10-31 |
| WO2007140212A3 (en) | 2008-12-24 |
| AU2007202359A1 (en) | 2007-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1860101T3 (pl) | Sól winianu izofagominy i sposoby zastosowania | |
| ZA200804030B (en) | Improved process for the preparation of 4-(benzimidazolylmethylamino)benzamides and the salts thereof | |
| EA200702208A1 (ru) | Ингибиторы дипептидилпептидазы-iv | |
| IL210577A (en) | Compound 1,2,3,4-tetrahydrocyclopenta [b] indole-3-yl acetic acid, salt, hydrate and solvent, pharmaceutical, compound, salt, hydrate, solvent or pharmaceutical for use as a medicine or treatment Salt, hydrate, solvent or pharmaceutical preparation in the manufacture of a drug and process for the preparation | |
| ATE530519T1 (de) | Cyclobutylaminderivate | |
| MXPA05012678A (es) | Forma cristalina del agonista del receptor adrenergico beta2. | |
| NO20081905L (no) | Benzotiazolcyklobutylaminderivater og deres anvendelse som histamin-3-reseptorligander | |
| PL1617834T3 (pl) | Kompozycja farmaceutyczna zawierająca mleczan i jej zastosowania | |
| PL1960379T3 (pl) | Pochodne N-(1-alkilo-2-fenyloetylo)-karboksamidu i ich zastosowanie jako fungicydów | |
| IL186465A0 (en) | Process for preparing levetiracetam and racemization of (r)-and(s)-2-amino butynamide and the corresponding acid derivatives | |
| BRPI0415164A (pt) | dispositivo para administrar uma composição bioterapêutica, composição bioterapêutica, método de preparação de uma composição bioterapêutica, método de tratamento, e dispensador | |
| UA97122C2 (ru) | Кристаллическая форма миндальной кислоты как ингибитор тромбина (варианты) | |
| SI1881818T1 (sl) | Sestavek za zdravljenje odstopa mrežnice in metoda za njegovo izdelavo | |
| UA88481C2 (ru) | Донепезила фумарат, пригодный для получения фармацевтических композиций | |
| WO2010101301A9 (en) | Prophylaxis and treatment of macular degeneration and retinopathy using a prdx protein | |
| WO2005062992A3 (en) | Substituted melatonin derivatives, process for their preparation, and methods of use | |
| UA94042C2 (ru) | Применение агомелатина в получении лекарственных средств, предназначенных для лечения синдрома смита-магениса | |
| MXPA06007007A (es) | Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores. | |
| WO2010038948A3 (en) | Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders | |
| IL184383A0 (en) | A pharmaceutical composition for the treatment of lysosomal storage disorder, a method for the manufacture thereof and a kit containing the same | |
| DE60331654D1 (de) | Nicht-radioaktives Strontiummittel zur Behandlung von Krebs | |
| DE602007010926D1 (de) | Neues verfahren zur herstellung von ammoniumsalzen von esomeprazol | |
| HU0500975D0 (en) | Process for producing of extract of sour cherry seed, use of extract for producing of medicament and medicaments consist extract | |
| PL1716128T3 (pl) | Podstawione związki 4,5,6,7-tetrahydrobenzotiazol-2-iloaminy | |
| ATE451367T1 (de) | Verfahren zur herstellung von ziprasidon |